Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder

Michael R. Littner, Clete Kushida, W. McDowell Anderson, Dennis Bailey, Richard B. Berry, Max Hirshkowitz, Sheldon Kapen, Milton Kramer, Teofilo Lee-Chiong, Kasey K. Li, Daniel L. Loube, Timothy Ian Morgenthaler, Merrill Wise

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

Dopaminergic agents, particularly dopamine agonists, have been used with increasing frequency in the treatment of restless legs syndrome and periodic limb movement disorder. These evidence-based practice parameters are complementary to the Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, published in 1999.1 These practice parameters were developed by the Standards of Practice Committee and reviewed and approved by the Board of Directors of the American Academy of Sleep Medicine. Recommendations are based on the accompanying comprehensive review of the medical literature regarding the dopaminergic treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), which was developed by a task force commissioned by the American Academy of Sleep Medicine. The following recommendations serve as a guide to the appropriate use of dopaminergic agents in the treatment of RLS and PLMD. Levodopa with decarboxylase inhibitor, and the dopaminergic agonists pergolide, pramipexole, and ropinirole are effective in the treatment of RLS and PLMD. Other dopamine agonists (talipexole, cabergoline, piribidel, and alpha-dihydroergocryptine) and the dopaminergic agents amantadine and selegiline may be effective in the treatment of RLS and PLMD, but the level of effectiveness of these medications is not currently established. Lastly, no specific recommendations can be made regarding dopaminergic treatment of children or pregnant women with RLS or PLMD.

Original languageEnglish (US)
Pages (from-to)557-559
Number of pages3
JournalSleep
Volume27
Issue number3
StatePublished - 2004

Fingerprint

Nocturnal Myoclonus Syndrome
Restless Legs Syndrome
Dopamine Agents
Dopamine Agonists
Therapeutics
Sleep
Dihydroergocryptine
Pergolide
Medicine
Selegiline
Amantadine
Carboxy-Lyases
Evidence-Based Practice
Levodopa
Advisory Committees
Pregnant Women

Keywords

  • Dopamine agonists
  • Dopaminergic agents
  • Periodic limb movement disorder
  • Restless legs syndrome

ASJC Scopus subject areas

  • Physiology

Cite this

Littner, M. R., Kushida, C., Anderson, W. M., Bailey, D., Berry, R. B., Hirshkowitz, M., ... Wise, M. (2004). Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep, 27(3), 557-559.

Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. / Littner, Michael R.; Kushida, Clete; Anderson, W. McDowell; Bailey, Dennis; Berry, Richard B.; Hirshkowitz, Max; Kapen, Sheldon; Kramer, Milton; Lee-Chiong, Teofilo; Li, Kasey K.; Loube, Daniel L.; Morgenthaler, Timothy Ian; Wise, Merrill.

In: Sleep, Vol. 27, No. 3, 2004, p. 557-559.

Research output: Contribution to journalArticle

Littner, MR, Kushida, C, Anderson, WM, Bailey, D, Berry, RB, Hirshkowitz, M, Kapen, S, Kramer, M, Lee-Chiong, T, Li, KK, Loube, DL, Morgenthaler, TI & Wise, M 2004, 'Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder', Sleep, vol. 27, no. 3, pp. 557-559.
Littner MR, Kushida C, Anderson WM, Bailey D, Berry RB, Hirshkowitz M et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep. 2004;27(3):557-559.
Littner, Michael R. ; Kushida, Clete ; Anderson, W. McDowell ; Bailey, Dennis ; Berry, Richard B. ; Hirshkowitz, Max ; Kapen, Sheldon ; Kramer, Milton ; Lee-Chiong, Teofilo ; Li, Kasey K. ; Loube, Daniel L. ; Morgenthaler, Timothy Ian ; Wise, Merrill. / Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. In: Sleep. 2004 ; Vol. 27, No. 3. pp. 557-559.
@article{9c12b610447c440d8646ff26db93aca6,
title = "Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder",
abstract = "Dopaminergic agents, particularly dopamine agonists, have been used with increasing frequency in the treatment of restless legs syndrome and periodic limb movement disorder. These evidence-based practice parameters are complementary to the Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, published in 1999.1 These practice parameters were developed by the Standards of Practice Committee and reviewed and approved by the Board of Directors of the American Academy of Sleep Medicine. Recommendations are based on the accompanying comprehensive review of the medical literature regarding the dopaminergic treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), which was developed by a task force commissioned by the American Academy of Sleep Medicine. The following recommendations serve as a guide to the appropriate use of dopaminergic agents in the treatment of RLS and PLMD. Levodopa with decarboxylase inhibitor, and the dopaminergic agonists pergolide, pramipexole, and ropinirole are effective in the treatment of RLS and PLMD. Other dopamine agonists (talipexole, cabergoline, piribidel, and alpha-dihydroergocryptine) and the dopaminergic agents amantadine and selegiline may be effective in the treatment of RLS and PLMD, but the level of effectiveness of these medications is not currently established. Lastly, no specific recommendations can be made regarding dopaminergic treatment of children or pregnant women with RLS or PLMD.",
keywords = "Dopamine agonists, Dopaminergic agents, Periodic limb movement disorder, Restless legs syndrome",
author = "Littner, {Michael R.} and Clete Kushida and Anderson, {W. McDowell} and Dennis Bailey and Berry, {Richard B.} and Max Hirshkowitz and Sheldon Kapen and Milton Kramer and Teofilo Lee-Chiong and Li, {Kasey K.} and Loube, {Daniel L.} and Morgenthaler, {Timothy Ian} and Merrill Wise",
year = "2004",
language = "English (US)",
volume = "27",
pages = "557--559",
journal = "Sleep",
issn = "0161-8105",
publisher = "American Academy of Sleep Medicine",
number = "3",

}

TY - JOUR

T1 - Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder

AU - Littner, Michael R.

AU - Kushida, Clete

AU - Anderson, W. McDowell

AU - Bailey, Dennis

AU - Berry, Richard B.

AU - Hirshkowitz, Max

AU - Kapen, Sheldon

AU - Kramer, Milton

AU - Lee-Chiong, Teofilo

AU - Li, Kasey K.

AU - Loube, Daniel L.

AU - Morgenthaler, Timothy Ian

AU - Wise, Merrill

PY - 2004

Y1 - 2004

N2 - Dopaminergic agents, particularly dopamine agonists, have been used with increasing frequency in the treatment of restless legs syndrome and periodic limb movement disorder. These evidence-based practice parameters are complementary to the Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, published in 1999.1 These practice parameters were developed by the Standards of Practice Committee and reviewed and approved by the Board of Directors of the American Academy of Sleep Medicine. Recommendations are based on the accompanying comprehensive review of the medical literature regarding the dopaminergic treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), which was developed by a task force commissioned by the American Academy of Sleep Medicine. The following recommendations serve as a guide to the appropriate use of dopaminergic agents in the treatment of RLS and PLMD. Levodopa with decarboxylase inhibitor, and the dopaminergic agonists pergolide, pramipexole, and ropinirole are effective in the treatment of RLS and PLMD. Other dopamine agonists (talipexole, cabergoline, piribidel, and alpha-dihydroergocryptine) and the dopaminergic agents amantadine and selegiline may be effective in the treatment of RLS and PLMD, but the level of effectiveness of these medications is not currently established. Lastly, no specific recommendations can be made regarding dopaminergic treatment of children or pregnant women with RLS or PLMD.

AB - Dopaminergic agents, particularly dopamine agonists, have been used with increasing frequency in the treatment of restless legs syndrome and periodic limb movement disorder. These evidence-based practice parameters are complementary to the Practice Parameters for the Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder, published in 1999.1 These practice parameters were developed by the Standards of Practice Committee and reviewed and approved by the Board of Directors of the American Academy of Sleep Medicine. Recommendations are based on the accompanying comprehensive review of the medical literature regarding the dopaminergic treatment of restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), which was developed by a task force commissioned by the American Academy of Sleep Medicine. The following recommendations serve as a guide to the appropriate use of dopaminergic agents in the treatment of RLS and PLMD. Levodopa with decarboxylase inhibitor, and the dopaminergic agonists pergolide, pramipexole, and ropinirole are effective in the treatment of RLS and PLMD. Other dopamine agonists (talipexole, cabergoline, piribidel, and alpha-dihydroergocryptine) and the dopaminergic agents amantadine and selegiline may be effective in the treatment of RLS and PLMD, but the level of effectiveness of these medications is not currently established. Lastly, no specific recommendations can be made regarding dopaminergic treatment of children or pregnant women with RLS or PLMD.

KW - Dopamine agonists

KW - Dopaminergic agents

KW - Periodic limb movement disorder

KW - Restless legs syndrome

UR - http://www.scopus.com/inward/record.url?scp=2542499461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542499461&partnerID=8YFLogxK

M3 - Article

C2 - 15164914

AN - SCOPUS:2542499461

VL - 27

SP - 557

EP - 559

JO - Sleep

JF - Sleep

SN - 0161-8105

IS - 3

ER -